U.S. markets open in 6 hours 57 minutes
  • S&P Futures

    4,297.50
    -44.00 (-1.01%)
     
  • Dow Futures

    33,780.00
    -275.00 (-0.81%)
     
  • Nasdaq Futures

    13,958.75
    -199.75 (-1.41%)
     
  • Russell 2000 Futures

    1,944.40
    -28.30 (-1.43%)
     
  • Crude Oil

    86.81
    -0.54 (-0.62%)
     
  • Gold

    1,811.40
    -18.30 (-1.00%)
     
  • Silver

    23.19
    -0.61 (-2.57%)
     
  • EUR/USD

    1.1217
    -0.0028 (-0.25%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3424
    -0.0038 (-0.28%)
     
  • USD/JPY

    114.6950
    +0.0350 (+0.03%)
     
  • BTC-USD

    36,246.91
    -977.18 (-2.63%)
     
  • CMC Crypto 200

    826.16
    -29.65 (-3.46%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,170.30
    -841.03 (-3.11%)
     

Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • NRIX
  • SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%.

  • Analyst Christopher Liu notes that Nurix presented preliminary NX-2127 pharmacokinetics/pharmacodynamics data.

  • Liu believes that this data is "encouraging," as the asset, at the second dose level of 200 mg QD, demonstrated 91%-plus BTK degradation, which is similar to or higher than the BTK occupancy rate for BTK inhibitors.

  • In addition, no key adverse events associated with BTK inhibitors were observed, which could facilitate differentiation in CLL and potentially open up the DLBCL opportunity, he contends.

  • As a result, the analyst increased his weighted average probability of success for NX-2127 in CLL from 23% to 33%.

  • Last week, SVB initiated coverage on Nurix with a price target of $50, an upside of approximately 50%.

  • Price Action: NRIX shares are up 18.50% at $34.31 during the market session on the last check Wednesday.

Latest Ratings for NRIX

Oct 2021

SVB Leerink

Maintains

Outperform

Oct 2021

SVB Leerink

Initiates Coverage On

Outperform

Apr 2021

RBC Capital

Initiates Coverage On

Outperform

View More Analyst Ratings for NRIX
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.